<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089270</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-10-EES-0519-CTIL</org_study_id>
    <nct_id>NCT01089270</nct_id>
  </id_info>
  <brief_title>Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson Disease is one of the most common neurodegenerative illnesses. First degree
      relatives of Parkinson patient are in high risk for developing the disease. We will try to
      detect early changes in brain metabolism before the appearance of Parkinson symptoms.

      Participants: first degree relatives of diagnosed Parkinson patients that carry a gene
      mutation in either LRRK2 or GBA genes.

      The examination results will be given to the participants by a doctor from the neurology
      department.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        First degree relatives of diagnosed Parkinson patients that carry either LRRK2 or GBA gene
        mutation.

        Ages: 30-80
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy first degree relatives of diagnosed Parkinson patients

        Exclusion Criteria:

          -  patients unable to understand and sign an informed consent

          -  minors

          -  people with psychiatric disorders or a history of major head trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Even-Sapir, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Sourasky Medical Center, Tel Aviv, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Einat Even-sapir, PhD, MD</last_name>
    <phone>972-3-6974444</phone>
    <phone_ext>3536</phone_ext>
    <email>evensap@tasmc.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayelet Kurzband, BA</last_name>
    <phone>972-3-6974444</phone>
    <phone_ext>3536</phone_ext>
    <email>ayeletk@tasmc.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Einat Even-Sapir, MD, PhD</last_name>
      <phone>972-3-6974444</phone>
      <phone_ext>3536</phone_ext>
      <email>Evensap@tasmc.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Ayelet Kurzband, BA</last_name>
      <phone>972-3-6974444</phone>
      <phone_ext>3536</phone_ext>
      <email>ayeletk@tasmc.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Hedva Lerman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nir Giladi, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anat Milerman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields SD, Gur R. Dopamine transporters decrease with age. J Nucl Med. 1996 Apr;37(4):554-9.</citation>
    <PMID>8691238</PMID>
  </reference>
  <reference>
    <citation>Huang Y, Cheung L, Rowe D, Halliday G. Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev. 2004 Aug;46(1):44-70. Review.</citation>
    <PMID>15297154</PMID>
  </reference>
  <reference>
    <citation>Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med. 2004 Jul;10 Suppl:S58-62. Review.</citation>
    <PMID>15272270</PMID>
  </reference>
  <reference>
    <citation>von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77. Review.</citation>
    <PMID>15236834</PMID>
  </reference>
  <reference>
    <citation>Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM. LRRK2 mutations in Parkinson disease. Neurology. 2005 Sep 13;65(5):738-40.</citation>
    <PMID>16157908</PMID>
  </reference>
  <reference>
    <citation>Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology. 2007 Oct 16;69(16):1595-602.</citation>
    <PMID>17938369</PMID>
  </reference>
  <reference>
    <citation>Herholz K, Heiss WD. Positron emission tomography in clinical neurology. Mol Imaging Biol. 2004 Jul-Aug;6(4):239-69. Review.</citation>
    <PMID>15262239</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>March 17, 2010</last_update_submitted>
  <last_update_submitted_qc>March 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Einat Even-Sapir MD, PhD. Head, Dept of Nuclear Medicine</name_title>
    <organization>Tel Aviv Sourasky Medical Center</organization>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>fdg pet-ct</keyword>
  <keyword>i123 dat scan</keyword>
  <keyword>first degree relatives of diagnosed Parkinson patients</keyword>
  <keyword>with no clinical evidence of movement disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

